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Abstract 
Over the last decade there has been an 
increasing realisation that oxygen should be 
considered a drug which is prescribed for specific 
indications to achieve a specific oxygen saturation 
range, and that the response needs to be monitored 
to guide ongoing therapy. This realisation has led to 
the development and promotion of guidelines which 
provide simple, practical and evidence-based 
recommendations for the acute use of oxygen in 
adults in clinical practice. In this commentary the 
Thoracic Society of Australia and New Zealand 
(TSANZ) oxygen guidelines are reviewed, and the 
key concepts and recommendations are presented.  
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Abbreviations 
ABG: Arterial blood gas 
BTS: British Thoracic Society 
COPD: Chronic obstructive pulmonary disease 
CPAP: Continuous positive airway pressure 
ED: Emergency department 
FiO2: Fraction of inspired oxygen 
HDU: High dependency unit 
HFNC: High flow nasal cannulae 
ICU: Intensive care unit 
MDI: Metered-dose inhaler 
NIV: Non-invasive ventilation 
PaCO2: Arterial partial pressure of carbon 
dioxide 
PaO2: Arterial partial pressure of oxygen 
SaO2: Arterial oxygen saturation measured 
by arterial blood gas 
SpO2: Arterial oxygen saturation measured 
by pulse oximetry 
TSANZ: Thoracic Society of Australia and New 
Zealand 
 
 Oxygen is one of the most commonly 
administered medications in patients receiving 
emergency or hospital based care. It is probably 
also one of the most commonly misused 
medications, being frequently administered in high 
concentrations to patients who are not hypoxaemic 
and in whom its use is not indicated. This has led to 
calls for oxygen to be considered a medication that 
is prescribed and administered for specific 
indications, delivered through a specific device,  at 
specific flow rates to achieve a documented target 
oxygen saturation range, with regular monitoring of 
the patient’s response.1-3 It has also led to the 
development and publication of evidence-based 
guidelines by professional societies such as the 
British Thoracic Society (BTS)4,5 and the Thoracic 
Society of Australia and New Zealand (TSANZ).6 
 The key concept on which the guidelines have 
been based is that there are risks associated with 
both hypoxaemia and hyperoxaemia, leading to the 
recommendation that oxygen should be prescribed 
only if required, and if so, to within a target oxygen 
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saturation range. In the TSANZ guidelines this 
practice has been referred to with the colloquial 
term ‘swimming between the flags’.6 In this 
commentary the TSANZ oxygen guidelines for 
acute oxygen use in adults are reviewed. The use of 
long term domiciliary oxygen for patients with 
severe chronic respiratory disease is not addressed, 
and it is recommended that the BTS guidelines for 
home oxygen use in adults are reviewed.7 
 
Key Concepts 
 There are a number of key concepts on which 
the TSANZ guidelines are based. The first is that 
oxygen therapy is a treatment for hypoxaemia, not 
breathlessness. Oxygen therapy does not relieve the 
sensation of breathlessness in the absence of 
hypoxaemia.  This has been shown in numerous 
clinical settings, with no clinical benefit of oxygen 
over room air for chronic obstructive pulmonary 
disease (COPD) patients with breathlessness who 
do not have severe hypoxaemia,8 or refractory 
breathlessness in the palliative setting.9 
Furthermore, routine high concentration oxygen 
therapy does not improve outcomes compared with 
room air or titrated oxygen therapy to relieve 
hypoxaemia, in the treatment of acute coronary 
syndrome,10 and hyperbaric oxygen does not reduce 
mortality risk after stroke.11 
 The second concept is that both hypoxaemia 
and hyperoxaemia may cause harm. Hypoxaemia is 
both a marker of the risk of a poor outcome due to 
the severity of the underlying disease(s) that has 
caused hypoxaemia, and an independent risk factor 
of poor outcome.12,13 While no absolute safe lower 
limit of hypoxaemia can be set, due to the differing 
clinical situations in which hypoxaemia can occur, 
oxygen therapy which achieves an arterial partial 
pressure of oxygen (PaO2) of at least 50 mmHg 
would prevent immediate life threatening risk from 
hypoxaemia.14   
 Risk associated with high concentration 
oxygen can relate to both the high fraction of 
inspired oxygen (FiO2) administered and the level 
of hyperoxaemia resulting from the high FiO2. 
Potential risks include adverse respiratory 
(increased arterial partial pressure of carbon dioxide 
(PaCO2), absorption atelectasis and direct 
pulmonary toxicity), cardiovascular (increased 
systemic vascular resistance and blood pressure, 
reduced coronary artery blood flow, reduced cardiac 
output), cerebrovascular (reduced cerebral blood 
flow) effects, and increased reperfusion injury due 
to increased reactive oxygen species.1,3,15,16   
 These competing risks at both ends of arterial 
oxygen tension have led to the ‘swimming between 
the flags’ concept of titrating oxygen therapy to 
within a specific target oxygen saturation range. It 
has also led to the proposal to realign the 
haemoglobin oxygen dissociation curve, to make 
the ‘slippery slope’ of oxygen desaturation less 
prominent, and accentuate the beneficial 
characteristics, enhancing both the pick-up of 
oxygen despite cardiovascular disease, and the drop 
off of oxygen to the tissues despite falling oxygen 
saturations (Figure 1). Through this different 
perspective of the haemoglobin oxygen dissociation 
curve, it might be possible to overcome the 
entrenched practice of doctors and other health 
professionals to administer high flow oxygen to 
breathless patients, regardless of whether 
hypoxaemia is present or not, for fear that the 
patient might get close to the ’slippery slope’.3,17     
 The third and related concept is that to achieve 
a target oxygen saturation range, pulse oximetry 
needs to be available in all clinical situations in 
which oxygen is used. However, clinicians need to 
be aware that the use of pulse oximetry to guide the 
titration of oxygen therapy is limited by its variable 
accuracy estimating arterial oxygen saturation 
(SaO2) in acutely ill patients, with oximetry 
measurements both over and under estimating 
SaO2, with wide limits of agreement.18-20 
 The fourth concept is that the use of high 
concentration oxygen in a breathless patient in an 
attempt to protect against hypoxaemia in the event 
of a subsequent deterioration has the potential to 
delay the recognition of such a deterioration.21 This 
clinical approach may provide a false reassurance 
that the patient is stable.  This is because there is 
unlikely to be any major change in vital signs22 or a 
marked decrease in SpO2 as assessed by pulse 
oximetry23 until a potentially life-threatening 
situation has developed.  At this stage there is 
limited opportunity to further increase the oxygen 
therapy while medical review and an intervention 
such as transfer to a high dependency unit (HDU) or 
intensive care unit (ICU) is undertaken. This is 
illustrated by the hypothetical modelling of a 
patient deteriorating following presentation with 
pneumonia (Figure 2). 
 
15
gOdRe 
 
 
 
Original Article 
 
 
 
Malta Medical Journal    Volume 29 Issue 02 2017                                                                                                                
 
 
Figure 1: Oxygen haemoglobin dissociation curve (reproduced with permission from 
reference 3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Left=traditional representation with “slippery slope” marked (SS) 
Right=curve realigned to show the two key characteristics: (a) haemoglobin maintains high levels of saturation 
despite marked reductions in arterial oxygen tension, and (b) oxygen tension remains relatively preserved as 
oxyhaemoglobin saturation declines. These characteristics result in pick-up of oxygen by haemoglobin being 
maintained despite reduced oxygen tension, and delivery of oxygen to tissues being maintained despite 
progressively falling oxyhaemoglobin saturation. 
 
 Similarly, if a patient who requires a high 
FiO2 to maintain adequate SpO2 deteriorates there is 
limited capacity to increase FiO2 to avoid life 
threatening hypoxaemia. For this reason, it is 
recommended that patients who need high FiO2’s 
should receive senior clinician review and transfer 
to an area where there are appropriate numbers of 
competent staff able to provide more intensive 
monitoring and therapy.  
 
Recommendations 
Based on these concepts 10 key 
recommendations were made for the use of oxygen 
therapy, as follows:  
1. Pulse oximetry should be available in all 
clinical situations in which oxygen is 
administered to patients.  While 
acknowledging the variable accuracy of SpO2 
in critically ill patients, an SpO2 of >92% is a 
practical lower threshold to rule out 
hypoxaemia, defined as an SaO2 <90%19 or a 
PaO2 <60mmHg (8 kPa).18   
2. In the immediate assessment of an acutely 
unwell patient, oxygen saturations should be 
measured by oximetry, pending the 
availability of blood gas results if required. 
Arterial blood gas (ABG) measurement 
should be considered in the following 
situations:  
x Critically ill patients with cardiorespiratory 
or metabolic dysfunction 
x In patients with an SpO2 <92% in whom 
hypoxaemia may be present  
x Deteriorating oxygen saturation requiring 
increased FiO2  
x Patients at risk of hypercapnia (see below) 
x Breathless patients in whom a reliable 
oximetry signal cannot be obtained. 
 Peripheral venous blood gas analysis is a less 
invasive test, however it does not provide an 
accurate estimate of PaCO2 or PaO2.24 It 
does, however, provide rapid clinically 
important information to assess acutely 
unwell patients, including pH, lactate, 
glucose, haemoglobin, sodium and 
potassium. In addition it provides a venous 
partial pressure of carbon dioxide which if 
less than <40 mmHg, effectively rules out 
hypercapnia. 24  
3. A specific oxygen prescription should be 
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documented in the patient records and the 
drug chart.25 The main requirement for an 
oxygen prescription is documentation of the 
target SpO2 range. 
4. An SpO2 target of 88% to 92% is 
recommended in exacerbations of COPD26 
and other conditions associated with chronic 
respiratory failure (such as obesity 
hypoventilation syndrome,27 bronchiectasis, 
cystic fibrosis,28 neuromuscular disease and 
chest wall deformities such as severe 
kyphoscoliosis). Where there is diagnostic 
uncertainty as to whether COPD is the 
primary cause of the exacerbation, it may be 
preferable to titrate oxygen therapy to the 88-
92% SpO2 target range.26,29,30   
5. In the presence of hypoxaemia in other acute 
medical conditions not associated with 
chronic respiratory failure, oxygen should be 
administered to achieve a target SpO2 range 
of 92% to 96%.31,32 There is considerable 
rationale for this range which is lower than 
the 94 to 98 % range recommended in the 
BTS guidelines.33 
6. Patients who need an estimated FiO2 of >0.40 
(such as >6 litres per minute via a simple 
face mask) to maintain an adequate SpO2 
should receive senior clinician review and 
may require transfer to a facility such as an 
HDU, where there are appropriate numbers 
of competent staff able to provide more 
intensive monitoring and therapy.  
7. Patients who need an estimated FiO2 of >0.50 
(such as >8 litres per minute via a simple 
face mask) to maintain an adequate SpO2 
should receive ICU review and most will 
require ICU transfer.  
8. For most patients standard nasal cannulae are 
the preferred method of oxygen delivery, 
with the flow rate varied to achieve the target 
oxygen saturation.  The main advantages of 
nasal cannulae are the ability to give 
nebulised bronchodilator at the same time as 
oxygen administration, and to prescribe 
oxygen at variable flows to achieve a target 
saturation range rather than a fixed FiO2.  
Humidified high flow nasal cannulae 
(HFNC) are an alternative to standard low 
flow nasal cannulae or high flow masks for 
oxygen delivery.34,35 There are no established 
evidence-based recommendations to guide 
appropriate clinical use in adults, however 
currently some centres recommend HFNC 
only in the emergency department (ED), 
HDU or ICU.     
9. In COPD and other conditions associated 
with chronic respiratory failure, if 
bronchodilator is required, the preferred 
methods of administration are via an air-
driven nebuliser or via a metered dose inhaler 
(MDI) r a spacer, with supplementary nasal 
oxygen continued as required.26,36 The reason 
for this is that the administration of 
bronchodilator via an oxygen-driven 
nebuliser has the potential to cause an 
increase in PaCO2.37,38 
10. In patients with hypercapnic respiratory 
failure, in whom an ABG measurement 
shows a pH <7.35 and PaCO2 >45 mmHg, 
non-invasive ventilation (NIV) or invasive 
ventilation should be considered.39-42 COPD 
patients with a pH <7.26 managed with NIV 
require more intensive monitoring with a low 
threshold for intubation (if appropriate).42 In 
patients with severe cardiogenic pulmonary 
oedema continuous positive airway pressure 
(CPAP) should be considered.43 It is 
recommended that patients receiving 
ventilatory support are located in a ward area 
such as an HDU, ICU, a close observation 
unit or monitored bed unit, where there are 
adequate numbers of staff experienced in 
ventilatory support to provide an appropriate 
level of monitoring and titration of therapy.39  
 
 A practical assessment and treatment 
algorithm was developed, encompassing these key 
concepts and recommendations, as displayed in 
Figure 3. It is suggested that the algorithm is 
modified as required to meet the needs of different 
health care settings.  
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Figure 2: Case example illustrating the potential for the ‘prophylactic’ administration of high flow 
oxygen to delay recognition of deteriorating cardiorespiratory function (reproduced with permission from 
reference 21) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The hypothetical case example of a patient with community acquired pneumonia presenting to medical care 
with a baseline SpO2 of 88% (PaO2 58mmHg).  The patient then deteriorates, with the intrapulmonary shunt 
increasing at a rate of 1% per 6 minutes. Two initial therapeutic approaches to oxygen therapy are considered, 
with an FiO2 of (a) 0.3 and (b) 0.6. 
In example (a), with an FiO2 of 0.3, the time required for the PaO2 to decrease from 80mmHg (SpO2 95%) to 
<60mmHg (SpO2 <90%) is around 60 minutes.  At this stage, with the same rate of increasing intrapulmonary 
shunt, an increase in FiO2 from 0.3 to 0.6 will maintain the PaO2 above 60mmHg for about a further 60 
minutes. 
In example (b), if the patient receives an FiO2 of 0.6 it would take around 120 minutes for the PaO2 to decrease 
to <60mmHg (SpO2 <90%).  At this stage, with the same rate of increasing intrapulmonary shunt, there will be 
a further deterioration in PaO2 despite maintenance of the FiO2 at 0.6.   
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Figure 3:  Treatment algorithm for oxygen therapy (reproduced with permission from reference 6) 
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